Market & financial news desk
NovoCure Ltd. (NVCR) was the market's strongest performer Thursday, jumping roughly 25% to trade near $19.40. The move followed second-quarter results that exceeded expectations and full-year sales guidance raised above prior estimates.
Why It Matters More Than Usual
The rebound carries added weight because of where the stock had been. In June, NovoCure fell about 20% in a single session after its Phase 3 TRIDENT trial — testing earlier use of its Tumor Treating Fields therapy in newly diagnosed glioblastoma — failed to show a statistically significant overall survival benefit. That result shifted the investment case from pipeline-driven upside toward execution on approved indications.
The Underlying Business
Thursday's report speaks to that execution. The company's TTFields platform has sustained double-digit revenue growth, and its commercial footprint has broadened well beyond its original glioblastoma indication — including Optune Lua for lung cancer and mesothelioma, and Optune Pax, approved in February 2026 for pancreatic cancer.
The Setup
Analysts had trimmed targets into the $20 to $23 range after the trial miss, leaving the stock trading at a steep discount to historical multiples. A quarter that demonstrates commercial momentum against those reset expectations is precisely the kind of result that produces an outsized move.